BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 30131000)

  • 1. Polycystic ovary syndrome in familial partial lipodystrophy type 2 (FPLD2): basic and clinical aspects.
    Gambineri A; Zanotti L
    Nucleus; 2018; 9(1):392-397. PubMed ID: 30131000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Familial partial lipodystrophy as differential diagnosis of polycystic ovary syndrome.
    Lewandowski KC; Lewiński A; Dąbrowska K; Jakubowski L; Gach A
    Endokrynol Pol; 2015; 66(6):550-4. PubMed ID: 26662654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenotypic diversity and glucocorticoid sensitivity in patients with familial partial lipodystrophy type 2.
    Resende ATP; Martins CS; Bueno AC; Moreira AC; Foss-Freitas MC; de Castro M
    Clin Endocrinol (Oxf); 2019 Jul; 91(1):94-103. PubMed ID: 30954027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Familial partial lipodystrophy (Dunnigan syndrome) due to LMNA gene mutation: The first description of its clinical case in Russia].
    Sorkina EL; Kalashnikova MF; Melnichenko GA; Tyulpakov AN
    Ter Arkh; 2015; 87(3):83-87. PubMed ID: 26027246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FPLD2 LMNA mutation R482W dysregulates iPSC-derived adipocyte function and lipid metabolism.
    Friesen M; Cowan CA
    Biochem Biophys Res Commun; 2018 Jan; 495(1):254-260. PubMed ID: 29108996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of LMNA in adipose: a novel mouse model of lipodystrophy based on the Dunnigan-type familial partial lipodystrophy mutation.
    Wojtanik KM; Edgemon K; Viswanadha S; Lindsey B; Haluzik M; Chen W; Poy G; Reitman M; Londos C
    J Lipid Res; 2009 Jun; 50(6):1068-79. PubMed ID: 19201734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fertility and obstetrical complications in women with LMNA-related familial partial lipodystrophy.
    Vantyghem MC; Vincent-Desplanques D; Defrance-Faivre F; Capeau J; Fermon C; Valat AS; Lascols O; Hecart AC; Pigny P; Delemer B; Vigouroux C; Wemeau JL
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2223-9. PubMed ID: 18364375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extracellular matrix remodeling and transforming growth factor-β signaling abnormalities induced by lamin A/C variants that cause lipodystrophy.
    Le Dour C; Wu W; Béréziat V; Capeau J; Vigouroux C; Worman HJ
    J Lipid Res; 2017 Jan; 58(1):151-163. PubMed ID: 27845687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Site-dependent differences in both prelamin A and adipogenic genes in subcutaneous adipose tissue of patients with type 2 familial partial lipodystrophy.
    Araújo-Vilar D; Lattanzi G; González-Méndez B; Costa-Freitas AT; Prieto D; Columbaro M; Mattioli E; Victoria B; Martínez-Sánchez N; Ramazanova A; Fraga M; Beiras A; Forteza J; Domínguez-Gerpe L; Calvo C; Lado-Abeal J
    J Med Genet; 2009 Jan; 46(1):40-8. PubMed ID: 18805829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Describing the natural history of clinical, biochemical and radiological outcomes of children with familial partial lipodystrophy type 2 (FPLD2) from the United Kingdom: A retrospective case series.
    Zhong ZX; Harris J; Wilber E; Gorman S; Savage DB; O'Rahilly S; Stears A; Williams RM
    Clin Endocrinol (Oxf); 2022 Dec; 97(6):755-762. PubMed ID: 35920656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of an integration-free induced pluripotent stem cell line (PUMCHi001-A) from a patient with familial partial lipodystrophy type 2 (FPLD2) carrying a heterozygous p.R349W (c.1045C > T) mutation in the LMNA gene.
    Xiao C; Yu M; Liu J; Wu H; Deng M; Zhang Q; Xiao X
    Stem Cell Res; 2020 Jan; 42():101651. PubMed ID: 31794942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-throughput Second-generation Sequencing Technology Assisted Diagnosis of Familial Partial Lipodystrophy (Type 2 Kobberling-Dunnigan Syndrome): A Case Report.
    Deng M; Chen W; Qi Y
    Comb Chem High Throughput Screen; 2024; 27(2):346-351. PubMed ID: 37231758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LMNA gene mutation as a model of cardiometabolic dysfunction: from genetic analysis to treatment response.
    Chirico V; Ferraù V; Loddo I; Briuglia S; Amorini M; Salpietro V; Lacquaniti A; Salpietro C; Arrigo T
    Diabetes Metab; 2014 Jun; 40(3):224-8. PubMed ID: 24485160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipodystrophy-linked LMNA p.R482W mutation induces clinical early atherosclerosis and in vitro endothelial dysfunction.
    Bidault G; Garcia M; Vantyghem MC; Ducluzeau PH; Morichon R; Thiyagarajah K; Moritz S; Capeau J; Vigouroux C; Béréziat V
    Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2162-71. PubMed ID: 23846499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The lipodystrophic hotspot lamin A p.R482W mutation deregulates the mesodermal inducer T/Brachyury and early vascular differentiation gene networks.
    Briand N; Guénantin AC; Jeziorowska D; Shah A; Mantecon M; Capel E; Garcia M; Oldenburg A; Paulsen J; Hulot JS; Vigouroux C; Collas P
    Hum Mol Genet; 2018 Apr; 27(8):1447-1459. PubMed ID: 29438482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adipocyte-Specific Deletion of Lamin A/C Largely Models Human Familial Partial Lipodystrophy Type 2.
    Corsa CAS; Walsh CM; Bagchi DP; Foss Freitas MC; Li Z; Hardij J; Granger K; Mori H; Schill RL; Lewis KT; Maung JN; Azaria RD; Rothberg AE; Oral EA; MacDougald OA
    Diabetes; 2021 Sep; 70(9):1970-1984. PubMed ID: 34088712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Familial partial lipodystrophy presenting as metabolic syndrome.
    Chan D; McIntyre AD; Hegele RA; Don-Wauchope AC
    J Clin Lipidol; 2016; 10(6):1488-1491. PubMed ID: 27919367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Dietary Intake, Leisure-Time Physical Activity, and Metabolic Profile in Women with Mutation in the LMNA Gene.
    Monteiro L; Foss-Freitas MC; Navarro A; Pereira F; Coeli F; Carneseca E; Júnior RM; Foss M
    J Am Coll Nutr; 2017; 36(4):248-252. PubMed ID: 28443701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel phenotypic expression associated with a new mutation in LMNA gene, characterized by partial lipodystrophy, insulin resistance, aortic stenosis and hypertrophic cardiomyopathy.
    Araújo-Vilar D; Lado-Abeal J; Palos-Paz F; Lattanzi G; Bandín MA; Bellido D; Domínguez-Gerpe L; Calvo C; Pérez O; Ramazanova A; Martínez-Sánchez N; Victoria B; Costa-Freitas AT
    Clin Endocrinol (Oxf); 2008 Jul; 69(1):61-8. PubMed ID: 18031308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regional Body Fat Changes and Metabolic Complications in Children With Dunnigan Lipodystrophy-Causing LMNA Variants.
    Patni N; Li X; Adams-Huet B; Vasandani C; Gomez-Diaz RA; Garg A
    J Clin Endocrinol Metab; 2019 Apr; 104(4):1099-1108. PubMed ID: 30418556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.